Adenoma Detection Rate (ADR) is a colonoscopy quality metric measuring the proportion of screening colonoscopies in which at least one adenoma (a precancerous polyp) is detected. Higher ADR is associated with better screening outcomes and lower interval cancer rates.
As a quality metric tied to a specific procedure, ADR offers a differentiated way to segment and target GI physicians beyond raw procedure volume.
For companies selling GI devices or AI-assisted polyp-detection technology, ADR is a uniquely relevant signal. AI detection tools aim to raise ADR, so identifying physicians and practices by their current performance points directly to the strongest prospects — those with room to improve or those already focused on quality.
ADR exemplifies quality-metric targeting: segmenting providers not just by how much they do, but by how well they do it — a sophisticated layer on top of volume-based targeting.
Adenoma detection rate (ADR) measures the percentage of screening colonoscopies in which a physician finds at least one adenoma (a precancerous polyp). It's a validated quality metric — higher ADR correlates with more effective screening and fewer missed cancers.
ADR benchmarks gastroenterologists by screening quality, letting teams identify high-performing physicians and those with room to improve. For quality-focused products, this segments the GI market by performance rather than by volume alone.
AI-assisted polyp-detection tools are designed to raise a physician's adenoma detection rate by flagging polyps that might be missed. ADR is therefore both the metric these tools aim to improve and a way to identify the best prospects for them.
Procedure volume targeting ranks physicians by how many colonoscopies they perform; ADR targeting ranks them by screening quality. Combining both finds high-volume physicians whose quality metrics indicate the best fit for a given product.